Senti Biosciences (SNTI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
13 Oct, 2026Executive summary
The virtual annual meeting was adjourned on October 8, 2026, without conducting business, despite a quorum; it is scheduled to reconvene October 15 at 8:00 a.m. Pacific time.
Voting matters and shareholder proposals
The adjournment allows more time to solicit votes in favor of the Merger Agreement Proposal; proposals are unchanged and polls remain open.
The record date remains September 23, 2026; stockholders who already voted and do not wish to change their vote need take no action.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Senti Biosciences
- All six proposals passed, including the merger, and three Class I directors were elected.SNTI
AGM 2026 - Merger approval sought with Celadon, with stockholders to receive milestone-based CVRs.SNTI
Proxy filing - Merger approval, CVRs, reverse split, and major share issuance up for stockholder vote.SNTI
Proxy filing - Amendment updates auditor consent for a public offering, with all signatures finalized.SNTI
Registration filing - Offering of 25.6M shares (82.1% of stock) triggers major dilution and strategic realignment.SNTI
Registration filing - Stockholders will receive contingent value rights in a merger, with future payments tied to SENTI-202 milestones.SNTI
Proxy filing - Convertible note and equity commitment secured, with shareholder vote pending on merger and CVR.SNTI
Proxy filing - Amended financing and merger plans address Nasdaq compliance and offer contingent value rights.SNTI
Proxy filing - Shareholders to vote on $4M convertible notes and potential $60M payout tied to SENTI-202 milestones.SNTI
Proxy filing